ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "axial spondyloarthritis"

  • Abstract Number: 2584 • 2014 ACR/ARHP Annual Meeting

    Smoking Is Not Associated with Response to TNF Blockers in Patients with Axial Spondyloarthritis

    Anna Dellyes1, Pierre Lafforgue1, Vincent Pradel2 and Thao Pham1, 1Rheumatology, APHM, Aix Marseille University, Marseille, France, 2Epidemiology, APHM, Aix Marseille University, Marseille, France

    Background/Purpose Smoking has been reported as associated with increase disease activity, more functional impairment, poorer quality of life and more radiographic damages in patients (pts)…
  • Abstract Number: 581 • 2014 ACR/ARHP Annual Meeting

    Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Etanercept in Axial Spondyloarthritis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

    Maxime Dougados1, Emily Wood2, Bernard Combe3, Corinne Miceli-Richard4, Francis Berenbaum5, Nandan Koppiker6, Arnaud Dubanchet7 and Isabelle Logeart7, 1Université Paris René Descartes and Hôpital Cochin, Paris, France, 2Biostatistics, Quanticate, Hitchin, England, 3Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 4Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, 5Service de Rhumatologie, Saint-Antoine Hospital, Paris, France, 6Pfizer PGRD, Sandwich, United Kingdom, 7Pfizer, Paris, France

    Background/Purpose Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line pharmacotherapy in axial spondyloarthritis (axSpA) but are recommended for use at the lowest effective dose for the shortest…
  • Abstract Number: 2581 • 2014 ACR/ARHP Annual Meeting

    Clinically Active Non-Radiographic Axial Spondyloarthritis Patients Who Initially Have a Negative MRI and Normal CRP May Develop a Positive MRI or Elevated CRP at a Later Timepoint

    Xenofon Baraliakos1, Joachim Sieper2, Su Chen3, Aileen L. Pangan3 and Jaclyn K. Anderson3, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3AbbVie Inc., North Chicago, IL

    Background/Purpose: Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) and active disease may have objective evidence of inflammation, either as bone marrow edema (BME) on magnetic…
  • Abstract Number: 580 • 2014 ACR/ARHP Annual Meeting

    MRI Is Often Negative in Clinically Suspected Non-Radiographic Axial Spondyloarthritis

    M.L. John1, M.a.C. van der Weijden1,2, C.M.a. van der Bijl1, S.T.G. Bruijnen1, C.J. van der Laken1, M.T. Nurmohamed1,2 and I.E. van der Horst-Bruinsma1, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

    Background/Purpose The diagnosis of ankylosing spondylitis (AS) is based on disease specific bone damage seen on plain radiography of the pelvis. Recent developments in magnetic…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology